556-10-5

Basic information

• Product Name: 4-NITROPHENYLUREA
• Synonyms: 4-NITROPHENYLUREA;N-(p-Nitrophenyl)urea;1-(4-Nitrophenyl)urea;1-(p-Nitrophenyl)urea;ENT 61327;NSC 227938;p-Nitrophenylurea
• CAS NO: 556-10-5
• Molecular Formula: C₇H₇N₃O₃
• Molecular Weight: 181
• Mol File: 556-10-5.mol
• Article Data: 24

Chemical Properties

• Melting Point: 150℃
• Boiling Point: 314.24°C (rough estimate)
• Flash Point: 160.2°C
• Appearance: /
• Density: 1.490
• Vapor Pressure: 8.15E-05mmHg at 25°C
• Refractive Index: 1.5860 (estimate)
• Solubility: soluble in Methanol,Ethanol,Dimethylformamide
• PKA: 13.79±0.70(Predicted)
• Merck: 14,6626
• CAS DataBase Reference: 4-NITROPHENYLUREA(CAS DataBase Reference)
• NIST Chemistry Reference: 4-NITROPHENYLUREA(556-10-5)
• EPA Substance Registry System: 4-NITROPHENYLUREA(556-10-5)

Safety Data

• Hazardous Substances Data: 556-10-5(Hazardous Substances Data)

Usage

Purification Methods

Crystallise the urea from EtOH or hot water. UV has max at 322nm (EtOH). [Beilstein 12 II 392, 12 III 1617, 12 IV 1645.]

InChI:InChI=1/C7H7N3O3/c8-7(11)9-5-1-3-6(4-2-5)10(12)13/h1-4H,(H3,8,9,11)

Upstream product

• 100-28-7 4-Nitrophenyl isocyanate 
• 62-23-7 4-nitro-benzoic acid 
• 14213-11-7 1-(4-nitrophenyl)-1H-tetrazole 
• 619-80-7 4-nitrobenzamide 
• 192332-48-2 N'-hydroxy-4-nitrobenzimidamide 
• 619-72-7 4-nitrobenzonitrile 
• 100-00-5 4-chlorobenzonitrile 
• 693831-23-1 C₁₅H₁₅N₃O₄ 
• 3696-22-8 p-nitrophenylthiourea 
• 100-01-6 4-nitro-aniline 
• 6275-84-9 1,2,3,4-Tetrahydro-2,4-dioxo-1-phenyl-5-pyrimidincarbonitril 
• 2733-41-7 4-nitrobenzoyl azide 
• 29177-55-7 N-carbamoyl-4-nitrobenzenesulfonamide 
• 7647-01-0 hydrogenchloride 

Downstream Products

• 144921-43-7 N-4-Nitrophenyl-N',N'-dioctylurea 
• 1432624-40-2 2-(3,4,5-trimethoxystyryl)-4-(4-nitrophenylureido)-quinazoline 
• 96236-88-3 N-(4-nitrophenyl)-N'-methoxymethylurea 
• 27425-04-3 1-(4-nitrophenyl)barbituric acid 
• 26946-72-5 N-(4-nitrophenyl)-1,3-benzoxazol-2-amine 
• 1401252-80-9 3-(4-nitrophenylureido)carbonyl-N₁-ethyl-6-hydroxy-4-oxo-pyrido[2,3-h]quinoline 
• 13915-23-6 1-(2-methyl-4-oxo-4H-quinazolin-3-yl)-3-(4-nitro-phenyl)-urea 
• 1227464-98-3 2-{(coumarin-3-yl-1,3,4-oxadiazolyl)-5-thio}-4-(morpholino)-6-(4-nitrophenylureido)-s-triazine 
• 1025365-03-0 2-(3-(2-thien-2-ylethyl)thioureido)-4-morpholin-4-yl-6-(3-(4-nitrophenyl)ureido)-s-triazine 

Relevant articles and documents

Templated synthesis of copper(II) azacyclam complexes using urea as a locking fragment and their metal-enhanced binding tendencies towards anions

Copper(II) azacyclam complexes 32+ and 42+ were obtained through a metal-templated procedure involving the pertinent open-chain tetramine, formaldehyde and a phenylurea derivative as a locking fragment. Both metal complexes can estab

Superparamagnetic Fe3O4 Nanoparticles in a Deep Eutectic Solvent: An Efficient and Recyclable Catalytic System for the Synthesis of Primary Carbamates and Monosubstituted Ureas

Superparamagnetic Fe3O4 nanoparticles were used to synthesize various primary carbamates as well as monosubstituted and N,N-disubstituted ureas. This efficient phosgene-free process used urea as an eco-friendly carbonyl source in the presence of a biocompatible deep eutectic solvent (DES) to provide an inexpensive and attractive route that afforded the products in moderate to excellent yields. The employed DES serves both a catalytic role and as the green reaction medium. The magnetic nanocatalyst and DES can been reused several times without a significant loss of activity.

Design and synthesis of novel N-(4-(Pyridin-2-yloxy)benzylidene)-4-[4-(substituted)phenyl]semicarbazides as potential anticonvulsant agents

A new series of N-(4-(pyridin-2-yloxy)benzylidene)-4-[4-(substituted)phenyl]semicarbazides (PSSD1-8) were designed and synthesized keeping in view the structural requirement of pharmacophore and evaluated for their possible anticonvulsant activity. All the derivatives were synthesized by the given scheme and reaction process was monitored by thin layer chromatography. The structure of synthesized derivatives was confirmed by FT-IR, 1H NMR, mass spectroscopy and elemental analysis. The anticonvulsant activity was established after intraperitoneal administration in MES and scMET seizure models. The most active compound of the series was 1-(4-(pyridin-2-yloxy)-benzylidene)-4-p-tolylsemicarbazide (PSSD5). A molecular docking study was carried out in order to assess the interaction and binding modes with target receptor/enzyme. Titled compounds were found to strongly bind to human gamma-aminobutyric acid receptor (GABAAR-β3). A computational study was also carried to predict the pharmacokinetic properties of the synthesized compounds.